Close Menu

Colorectal Cancer

News and reporting on colorectal cancer.

During a conference call, company executives also discussed results from the SMART NIPT trial and their outlook for Natera's three businesses.

The company doesn’t expect significant revenue from the test this year, but executives said that they are already seeing positive reception trends.

The company reported $112.4 million in revenues compared to $83.2 million in Q4 2019, beating the average Wall Street estimate of $106.6 million.

The sequencing test involves a single library preparation that is then split for parallel analysis of promoter methylation, MSI calculation, and gene mutation detection.

The company focuses on tests for early cancer screening tests and offers two fecal immunochemical tests approved in China.

The company is getting ready to offer cancer patients every type of molecular cancer diagnostics, including testing for minimal residual disease.

Exact's planned acquisition of Ashion, a sequencing lab based in Arizona, builds on the company's licensing of the TARDIS liquid biopsy technology from TGen in January.

The Spanish firm also expects to release clinical data on its early-stage, next-generation sequencing-based colorectal cancer test in the first half of 2021.

The final decision includes some changes, most notably removing requirements for guideline inclusion, but retains its technical performance benchmarks.

Last year, the company processed more than 1 million tests, most of them for its reproductive health business, but interest in Prospera and Signatera is growing. 

Pages

Nature News writes that additional details about the UK plan for an agency to support high-risk, high-reward science are needed.

The New York Times reports that the US Food and Drug Administration has authorized Johnson & Johnson's SARS-CoV-2 vaccine.

The Wall Street Journal writes new studies are giving glimpses into the origins of SARS-CoV-2.

In PLOS this week: analysis of Plasmodium population structure, qPCR assay to diagnose scabies, and more.